Search Result

Isoforms Recommended:	PPARγ

Results for "

PPAR-γ

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PPAR (330) Akt (10) Aldose Reductase (1) Aminopeptidase (1) AMPK (8) Amyloid-β (3) Androgen Receptor (4) Angiotensin Receptor (4) Antibiotic (4) Apoptosis (38) Aryl Hydrocarbon Receptor (1) Autophagy (19) Bacterial (16) Biochemical Assay Reagents (2) Bombesin Receptor (1) c-Myc (1) Calcium Channel (1) Cannabinoid Receptor (1) Caspase (2) COX (22) Cytochrome P450 (6) DNA Methyltransferase (1) DNA/RNA Synthesis (1) Drug Derivative (1) Drug Intermediate (2) Drug Metabolite (5) EGFR (1) Endogenous Metabolite (19) Epoxide Hydrolase (1) ERK (16) Estrogen Receptor/ERR (3) FABP (2) Farnesyl Transferase (1) Fatty Acid Synthase (FASN) (1) Ferroptosis (21) Fluorescent Dye (1) Free Fatty Acid Receptor (4) Fungal (4) Glucocorticoid Receptor (1) GLUT (5) Glutathione Peroxidase (1) Glycosidase (4) GSK-3 (1) HDAC (2) HIF/HIF Prolyl-Hydroxylase (3) HIV (2) HSV (1) Influenza Virus (1) Insulin Receptor (1) Integrin (2) Interleukin Related (14) Isotope-Labeled Compounds (25) JNK (5) Keap1-Nrf2 (6) Leukotriene Receptor (1) Ligands for Target Protein for PROTAC (1) Lipoxygenase (1) LXR (5) MEK (2) Mitochondrial Metabolism (7) Monoamine Oxidase (1) mTOR (2) NF-κB (31) NO Synthase (8) NOD-like Receptor (NLR) (2) Nuclear Hormone Receptor 4A/NR4A (2) Orthopoxvirus (1) P-glycoprotein (2) p38 MAPK (2) PAK (8) Parasite (2) PARP (3) PCSK9 (2) PGC-1α (2) PGE synthase (1) Phosphatase (2) PI3K (3) PKC (2) Potassium Channel (4) Prolyl Endopeptidase (PREP) (2) Prostaglandin Receptor (5) PTEN (2) Pyroptosis (2) Raf (1) RAR/RXR (5) Ras (1) Reactive Oxygen Species (ROS) (10) Reference Standards (39) ROCK (4) ROR (1) Sirtuin (3) Small Interfering RNA (siRNA) (3) SOD (1) Src (2) STAT (6) Tau Protein (1) TGF-beta/Smad (3) TGF-β Receptor (1) TNF Receptor (6) Toll-like Receptor (TLR) (4) TRP Channel (11) VD/VDR (1) Wnt (2) β-catenin (1)
By Research Areas:	Cancer (124) Cardiovascular Disease (45) Endocrinology (9) Infection (24) Inflammation/Immunology (110) Metabolic Disease (227) Neurological Disease (42)
Click Chemistry:	Alkynes (1)
Oligonucleotides:	Nucleoside Analogs (1) Inosine (1) Phospholipids (1) siRNA drugs (2) siRNAs (2)

365

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

PPARγ phosphorylation inhibitor 1	PPAR	Metabolic Disease
PPARγ phosphorylation inhibitor 1 (Compound 10) is a potent *PPARγ* binder with the IC₅₀ of 24 nM. PPARγ phosphorylation inhibitor 1 inhibits CDK5-mediated phosphorylation of PPARγ Ser273 with the IC₅₀ of 160 nM. PPARγ phosphorylation inhibitor 1 displays negligible PPARγ agonism in a reporter gene assay. Antidiabetic effects .

PPARγ agonist 5	PPAR	Cancer
PPARγ agonist 5 (Compound 1) is a potent and selective agonist of *PPARγ. PPARγ* agonist 5 has the potential for the research of cancer diseases .

PPARγ agonist 20	PPAR Glutathione Peroxidase SOD TNF Receptor Interleukin Related NF-κB	Infection Metabolic Disease Endocrinology
PPARγ agonist 20 is a potent, orally active *PPAR-γ* agonist. PPARγ agonist 20 effectively increases antioxidant defenses (SOD, GSH) and reduces lipid peroxidation. PPARγ agonist 20 can upregulate of Pparg, Glut4, and AdipoQ, suppresses of TNF-α, IL-6, and NF-κB p65. PPARγ agonist 20 significantly lowers fasting blood glucose, improving glucose tolerance, and restoring metabolic balance in Streptozotocin (HY-13753)-Nicotinamide (HY-B0150)-induced diabetic rats. PPARγ agonist 20 can be used for the study of type 2 diabetes .

PPARγ agonist 18	PPAR	Metabolic Disease Endocrinology
PPARγ agonist 18 (Compound (I)) is a *PPARγ* inhibitor (K_D: 3.75 μM). PPARγ agonist 18 can inhibit CDK5-mediated phosphorylation of PPARγ at Ser245. PPARγ agonist 18 can be used in insulin resistance research .

PPARγ modulator-2	PPAR	Metabolic Disease
PPARγ modulator-2 (Compound (R)-2n) is the reversible modulator for *PPARγ* that inhibits PPARγ ligand-binding domain (LBD) with an IC₅₀ of 41 nM. PPARγ modulator-2 reduces blood glucose, improves the glucose tolerance and insulin tolerance, and exhibits anti-diabetic efficacy in db/db mouse models .

PPARγ agonist 6	PPAR	Cancer
PPARγ agonist 6 (Compound 12) is a potent and selective agonist of *PPARγ. PPARγ* agonist 6 has the potential for the research of cancer diseases .

PPARγ agonist 3	PPAR	Cancer
PPARγ agonist 3 (Compound 18a) is a potent and selective agonist of *PPARγ. PPARγ* agonist 3 is not cytotoxic neither on non-resistant nor on resistant cells. PPARγ agonist 3 exerts antitumor potency only in combination with Imatinib .

PPARγ agonist 9	PPAR	Metabolic Disease
PPARγ agonist 9 is an agonist of *PPARγ. PPARγ* agonist 9 is the analogue of lysophosphatidic acid with an EC₅₀ more than 10 μM for LPA₃ receptor .

PPARγ agonist 4	PPAR	Cancer
PPARγ agonist 4 (Compound 18b) is a potent and selective agonist of *PPARγ. PPARγ* agonist 4 is not cytotoxic neither on non-resistant nor on resistant cells. PPARγ agonist 4 exerts antitumor potency only in combination with Imatinib .

PPARγ agonist 7	PPAR	Others
PPARγ agonist 7 (Compound 3a) is a potent and selective agonist of *PPARγ. PPARγ* agonist 7 promotes adiponectin production in human bone marrow mesenchymal stem cells (hBM-MSCs) as a novel PPARγ full agonist (EC₅₀, 4.34 μM) .

PPARγ agonist 8	PPAR	Metabolic Disease
PPARγ agonist 8 is an agonist of *PPARγ. PPARγ* agonist 8 induces peroxisome proliferator response element (PPRE)-luciferase activity with an EC₅₀ of 0.2 μM .

PPARγ agonist 12	PPAR	Metabolic Disease
PPARγ agonist 12 (compound 9i) is a potent and selective *PPARγ* agonist with EC₅₀s of 3.98 and 15.42 μM against *PPARγ* and PPARδ, respectively. PPARγ agonist 12 improves insulin secretion and has anti-diabetic effect .

PPARγ agonist 1	PPAR	Cardiovascular Disease Metabolic Disease
PPARγ agonist 1 (compound 15) is a potent agonist of *PPARγ. PPARγ* agonist 1 shows high efficacy to activate hPPARγ without raising a full agonism and probably avoiding adverse effects. PPARγ agonist 1 has the potential for the research of cardiovascular diseases associated with metabolic disorders .

PPARγ agonist 16	PPAR	Inflammation/Immunology
PPARγ agonist 16 (Compound 4G) is the agonist for *PPARγ, that competitively binds to LBD domain of PPARγ* with IC₅₀ of 1790 nM. PPARγ agonist 16 inhibits the ear swelling in mouse model, and exhibits anti-hyperglycemic in Streptozotocin (HY-13753)-induced mouse diabetes mellitus model .

PPARγ modulator-3	PPAR	Metabolic Disease
PPARγ modulator-3 (Compound 11) is a peroxisome proliferator-activated receptor γ (PPARγ) modulator with a K_D value of 186 nM. PPARγ modulator-3 is promising for research of insulin resistance (IR)-related diseases, such as type 2 diabetes mellitus (T2DM) and metabolic syndrome .

PPARγ agonist 2	PPAR	Metabolic Disease
PPARγ agonist 2 is a potent *PPARγ* partial agonist and can be used for metabolic disease research .

PPARγ agonist 11	PPAR	Metabolic Disease
PPARγ agonist 11 (compound 20) is a selective agonist of *PPARγ* (EC₅₀: 0.1 μM) .

PPARγ agonist 15	PPAR	Metabolic Disease
PPARγ agonist 15 (Compound 7c) is an agonist for *PPARγ. PPARγ* agonist 15 inhibits the expression of alpha-amylase (HPA) and alpha-glucosidase (HLAG) with IC₅₀ of 28.35 µM and 26.21 µM. PPARγ agonist 15 enhances glucose uptake in the L6 myotube cell. PPARγ agonist 15 improves glucose homeostasis, insulin sensitivity, and lipid metabolism in rat Streptozotocin (HY-13753)-induced diabetes model .

PPARγ agonist 17	PPAR	Cancer
PPARγ agonist 17 (Compound C1) is a *PPARγ* agonist. PPARγ agonist 17 enhances *PPARγ* activity and blocks the cell cycle in G2/M phase, inhibits cell migration and induces apoptosis in HT-29 cells. PPARγ agonist 17 has a broad spectrum anti-proliferative activity in cancer cells with relatively low toxicity in normal cells which cannot cross the blood-brain barrier .

PPARγ agonist 19	PPAR COX	Metabolic Disease
PPARγ agonist 19 (Compound 5e) is a *PPARγ* agonist. PPARγ agonist 19 has an IC₅₀ of 11.27 μM against COX-1 and an IC₅₀ of 0.05 μM against COX-1. PPARγ agonist 19 increases glucose uptake in rat hemidiaphragm assay and is superior to pioglitazone (HY-13956). PPARγ agonist 19 alleviates hyperglycemia and insulin resistance in an in vivo model of type 2 diabetes in rats and protects against renal and lipidemia damage caused by metabolic dysfunction .

PPARγ agonist 10	PPAR	Metabolic Disease
PPARγ agonist 10 (compound 33g) is a *PPARγ* agonist, and stimulats the insulin secretion, glucose uptake and insulin Sensitivity in βTC6 Cells .

PPARγ agonist 14	PPAR	Neurological Disease Metabolic Disease Inflammation/Immunology
PPARγ agonist 14 (compound 3) is a PPARy agonist (EC₅₀=2.4 μM) with anti-diabetic activity. PPARγ agonist 14 can improve intracellular glucose uptake, promote insulin release, and lower blood sugar. In addition, PPARγ agonist 14 also improves mitochondrial function, reduces oxidative stress, and inhibits inflammatory factors. PPARγ agonist 14 can be used in the study of neurodegenerative diseases, neuroinflammatory diseases, and other diseases .

PPARγ/δ modulator 2	PPAR	Metabolic Disease
PPARγ/δ modulator 2 (Compound 3h) is a *PPARγ* agonist and PPARδ antagonist. The K_i values for *PPARγ* and PPARδ are 2.8 μM and 43 nM, respectively. PPARγ/δ modulator 2 significantly enhances the production of Adiponectin and promotes adipogenic differentiation of human bone marrow mesenchymal stem cells (hBM-MSCs). PPARγ/δ modulator 2 can be used in the study of metabolic disorders associated with hypoadiponectinemia .

PPARγ modulator-1	PPAR	Metabolic Disease
Anticancer agent 183 (example 48) is a non-agonistic PPARG modulator. Anticancer agent 183 has a high affinity to PPARG (PPARγ). Anticancer agent 183 inhibits kinase-mediated phosphorylation of PPARG. Anticancer agent 183 can used for research on metabolic diseases to avoid side effects .

PPARγ-IN-5	PPAR	Inflammation/Immunology
PPARγ-IN-5 (Compound A3) is the inhibitor for *PPARγ. PPARγ-IN-5 inhibits lipid accumulation in hepatocytes without significant cytotoxicity in HepG2 cell (400 µM). PPAR*γ-IN-5 can be used in research of non-alcoholic fatty liver disease .

PPARγ/GR modulator 1	PPAR Glucocorticoid Receptor	Metabolic Disease
PPARγ/GR modulator 1 is an orally active dual agonist of *PPARγ* and glucocorticoid receptor (GR), with K_is of 3.3 and 33.6 μM, respectively. PPARγ/GR modulator 1 can be used for the research of metabolic diseases, such as diabetes .

PPARγ-IN-2	PPAR	Metabolic Disease
PPARγ-IN-2 (Compound 5a) is a *PPARγ* inhibitor. PPARγ-IN-2 inhibits TG accumulation in 3T3-L1 preadipocytes (EC₅₀: 0.106 μM). PPARγ-IN-2 inhibits high-cholesterol diet (HFC)-induced obesity and related metabolic syndrome, and reduces lipid accumulation in adipose tissue .

PPARγ-IN-3	PPAR	Metabolic Disease
PPARγ-IN-3 (compound 9ga) is a potent and orally active *PPARγ* inhibitor. PPARγ-IN-3 reduces triglyceride (TG) accumulation with low cytotoxicity. PPARγ-IN-3 preventes the excessive growth of body weight and lessened fat mass as well as liver mass, decreases lipid accumulation in the liver and blood. PPARγ-IN-3 has the potential for the research of diet-induced obesity .

PPARγ/δ modulator 1	PPAR	Metabolic Disease
PPARγ/δ modulator 1 (compound 3e) is a potent *PPAR* modulator. PPARγ/δ modulator 1 is a PPARδ antagonist and a PPARγ partial agonist , with K_i values of 14.4 nM and 5.31 μM, respectively. PPARγ/δ modulator 1 has the EC₅₀ of 7.3 and 12.6 μM for PPARδ corepression and adiponectin production, respectively .

Darglitazone CP-86325	PPAR	Neurological Disease Metabolic Disease
Darglitazone (CP-86325), a thiazolidinedione, is a potent, selective, and orally active *PPAR-γ* agonist. Darglitazone is effective in controlling blood glucose and lipid metabolism, and can be used for type II diabetes research .

GW1929 5+ Cited Publications	PPAR	Neurological Disease Metabolic Disease
GW 1929 is an orally active peroxisome proliferator-activated receptor-γ (PPARγ) agonist with a pK_i of 8.84 for human *PPAR-γ, and pEC₅₀s of 8.56 and 8.27 for human PPAR-γ* and murine *PPAR-γ*, respectively. GW 1929 (hydrochloride) has antidiabetic efficacy and neuroprotective potential .

GW1929 hydrochloride	PPAR	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
GW1929 hydrochloride is an orally active peroxisome proliferator-activated receptor-γ (PPARγ) agonist with a pK_i of 8.84 for human *PPAR-γ, and pEC₅₀s of 8.56 and 8.27 for human PPAR-γ* and murine *PPAR-γ, respectively. GW1929 hydrochloride has antidiabetic efficacy and neuroprotective potential. GW1929 hydrochloride suppresses neuronal apoptosis* and shows anti-inflammatory potential .

Darglitazone Sodium CP 86325 Sodium	PPAR	Neurological Disease Metabolic Disease
Darglitazone Sodium, a thiazolidinedione, is an orally active, potent, and selective *PPAR-γ* (peroxisome proliferator-activated receptor) agonist. Darglitazone Sodium is effective in controlling blood glucose and lipid metabolism, and can be used for type II diabetes research .

(±)-CBCQ Cannabichromenquinone	PPAR	Others
(±)-CBCQ is an oxidative product of cannabichromene, with an EC₅₀ of 14.7 μM for *PPAR-γ* .

7,8-Didehydrocimigenol	NF-κB PPAR	Cardiovascular Disease
7,8-Didehydrocimigenol is an active triterpenoid that can be isolated from Cimicifugae rhizoma. 7,8-Didehydrocimigenol inhibits TNF-α-induced VCAM-1 expression, inhibits NF-kB activity and phosphorylation of ERK1/2 and Akt, increases *PPAR-γ* expression. 7,8-Didehydrocimigenol can be used for the research of cardiovascular disorders such as atherosclerosis .

10-Nitrolinoleic acid	PPAR	Metabolic Disease Inflammation/Immunology Cancer
10-Nitrolinoleic acid is a potent peroxisome proliferator-activated receptor γ (PPARγ) *agonist. 10-Nitrolinoleic acid competes with [ ³H]Rosiglitazone for binding to PPAR-γ, with an IC₅₀* of 0.22 μM .**

Saikosaponin A 5 Publications Verification	LXR Bacterial	Inflammation/Immunology Cancer
Saikosaponin A is the main active ingredient in Bupleurum chinense, which can regulate lipid metabolism and promote cholesterol efflux in early atherosclerosis. In addition, Saikosaponin A may also serve as a potential peroxisome proliferator-activated receptor γ (PPAR-γ) agonist, significantly promoting the expression of *PPAR-γ*. Saikosaponin A can be used in the study of hyperlipidemic pancreatitis .

Candesartan 5 Publications Verification CV 11974	Angiotensin Receptor PPAR	Cardiovascular Disease Endocrinology Cancer
Candesartan (CV 11974) is an orally active angiotensin II AT1-Receptor blocker and *PPAR-γ* agonist. Candesartan has potent and long-lasting antihypertensive effects. Candesartan can be used for the research of hypertension, chronic heart failure (CHF) and Traumatic brain injury (TBI) .

Arhalofenate 1 Publications Verification MBX 102; JNJ 39659100	PPAR	Metabolic Disease
Arhalofenate (MBX 102) is a selective partial agonist of peroxisome proliferator-activated receptor *(PPAR)-γ*, used for the treatment of type 2 diabetes.

Alpinetin 5 Publications Verification	PPAR Keap1-Nrf2 Toll-like Receptor (TLR)	Infection Cardiovascular Disease Inflammation/Immunology Cancer
Alpinetin is a flavonoid isolated from cardamom and possesses antitumor, antiinflammation, hepatoprotective, cardiovascular protective, lung protective, antibacterial, antiviral, neuroprotective properties. Alpinetin inhibits lipopolysaccharide (LPS)-induced inflammation, activates *PPAR-γ*, activates Nrf2, and inhibits TLR4 expression to protect LPS-induced renal injury .

Angeloylgomisin H	PPAR	Metabolic Disease
Angeloylgomisin H, as a major lignin extract of Schisandra rubriflora, has the potential to improve insulin-stimulated glucose uptake by activating *PPAR-γ* .

Ginsenoside Rh1 4 Publications Verification Prosapogenin A2; Sanchinoside B2; Sanchinoside Rh1	Interleukin Related PPAR TNF Receptor Endogenous Metabolite	Inflammation/Immunology
Ginsenoside Rh1 (Prosapogenin A2) inhibits the expression of *PPAR-γ, TNF-α, IL-6, and IL-1β*.

Saikosaponin A (Standard)	Reference Standards LXR Bacterial	Metabolic Disease Inflammation/Immunology
Saikosaponin A (Standard) is the analytical standard of Saikosaponin A. This product is intended for research and analytical applications. Saikosaponin A is the main active ingredient in Bupleurum chinense, which can regulate lipid metabolism and promote cholesterol efflux in early atherosclerosis. In addition, Saikosaponin A may also act as a potential peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist, significantly promoting the expression of *PPAR-γ*. Saikosaponin A can be used in the study of hyperlipidemic pancreatitis .

Glycyrin	PPAR Bacterial	Infection Metabolic Disease
Glycyrin is a *PPAR-γ* ligand of licorice. Glycyrin can decrease the blood glucose levels of genetically diabetic mice. Glycyrin also shows antibacterial activity .

Alpinetin (Standard)	Reference Standards PPAR Keap1-Nrf2 Toll-like Receptor (TLR)	Infection Cardiovascular Disease Inflammation/Immunology Cancer
Alpinetin (Standard) is the analytical standard of Alpinetin. This product is intended for research and analytical applications. Alpinetin is a flavonoid isolated from cardamom and possesses antitumor, antiinflammation, hepatoprotective, cardiovascular protective, lung protective, antibacterial, antiviral, neuroprotective properties. Alpinetin inhibits lipopolysaccharide (LPS)-induced inflammation, activates PPAR-γ, activates Nrf2, and inhibits TLR4 expression to protect LPS-induced renal injury .

Apo-12'-lycopenal	PPAR	Metabolic Disease
Apo-12'-lycopenal is a Lycopene (HY-N0287) metabolite. Apo-12'-lycopenal promotes adipocyte differentiation and adiponectin secretion via *PPAR-γ* activation .

Cat. No.	Product Name	Type

HY-B1773A

Sodium propionate

2 Publications Verification

Biochemical Assay Reagents

Sodium propionate is an orally active short-chain fatty acid. Sodium propionate can be produced by intestinal bacteria from the metabolism of dietary fiber. Sodium propionate increases PPAR-γ, inhibits NF-κB activation, and reduces COX-2 expression and NO production. Sodium propionate also induces Apoptosis and Autophagy. Sodium propionate reduces HSV-1-induced keratitis. Sodium propionate has anticancer effects against glioblastoma. Sodium propionate exhibits neuroprotective, antioxidant, and anti-inflammatory activities. Sodium propionate can be used in the research of spinal cord injury and Alzheimer's disease .

Cat. No.	Product Name	Target	Research Area

HY-P10873

ST-CY14	Nuclear Hormone Receptor 4A/NR4A Mitochondrial Metabolism	Cancer
ST-CY14 is an inhibitor for **Nur77-PPARγ interaction with an EC₅₀ of 3.15 μM, that binds to Nur77 (K_d=32 nM), blocks Nur77** from being ubiquitinated and degraded by PPARγ, reduces fatty acid uptake and mitochondrial respiration, and inhibits the transcription of CD36 and FABP4. ST-CY14 inhibits the proliferation and migration of cancer cell MCF7 and MDA-MB-231. ST-CY14 inhibits tumor growth and bone metastasis in mouse models .

Species:	Human (6) Mouse (1)
Tag:	His (6) Tag Free (1) GST (1)
Source:	P. pastoris (1) Sf9 insect cells (1) E. coli (5)

Cat. No.	Compare	Product Name	Species	Source

HY-P7999

	PPAR gamma Protein, Human (His) 5+ Cited Publications PPAR-γ-LBD	Human	E. coli
	PPAR gamma LBD Protein, Human (His) is a His-fused PPAR-gamma-LBD protein expressed by E. coli, approximately 32.6 kDa. PPAR gamma LBD Protein can be used in the ligand screening assays, western blotting, and ELISA, et al.

HY-P700275

	PPAR gamma Protein, Human (C-His, solution) PPAR-γ-LBD	Human	E. coli
	The PPAR gamma protein is a nuclear receptor that binds to peroxisome proliferators and is activated upon ligand binding to specific PPREs on DNA. It regulates target gene transcription and controls fatty acid metabolism. PPAR gamma Protein, Human (C-His, solution) is the recombinant human-derived PPAR gamma protein, expressed by E. coli , with C-6*His labeled tag.

HY-P701336

	PPAR gamma Protein, Human PPARG; Peroxisome proliferator-activated receptor gamma; PPAR-gamma; Nuclear receptor subfamily 1 group C member 3	Human	E. coli
	The PPAR gamma protein is a nuclear receptor that binds to peroxisome proliferators and is activated upon ligand binding to specific PPREs on DNA. It regulates target gene transcription and controls fatty acid metabolism. PPAR gamma Protein, Human is the recombinant human-derived PPAR gamma protein, expressed by E. coli , with tag free.

HY-P702572

	PPAR gamma Protein, Human (P.pastoris, His) CIMT1, GLM1, NR1C31, PPARG2, PPARG5, PPARgamma, PPARG	Human	P. pastoris
	The PPAR gamma protein is a nuclear receptor that binds to peroxisome proliferators and is activated upon ligand binding to specific PPREs on DNA. It regulates target gene transcription and controls fatty acid metabolism. PPAR gamma Protein, Human (P.pastoris, His) is the recombinant human-derived PPAR gamma protein, expressed by P. pastoris , with N-6*His labeled tag.

HY-P73701

	PPAR gamma Protein, Human (sf9, His-GST) CIMT1; GLM1; NR1C31; PPARG2; PPARG5; PPARgamma; PPARG	Human	Sf9 insect cells
	The PPAR gamma protein is a nuclear receptor that binds to peroxisome proliferators and is activated upon ligand binding to specific PPREs on DNA. It regulates target gene transcription and controls fatty acid metabolism. PPAR gamma Protein, Human (sf9, His-GST) is the recombinant human-derived PPAR gamma protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag.

HY-P790012Y

	PPAR-gamma Protein, Human (271a.a, His, solution) CIMT1; GLM1; NR1C31; PPARG2; PPARG5; PPARgamma; PPARG	Human	E. coli
	The PPAR gamma protein is a nuclear receptor that binds to peroxisome proliferators and is activated upon ligand binding to specific PPREs on DNA. It regulates target gene transcription and controls fatty acid metabolism. PPAR-gamma Protein, Human (271a.a, His, solution) is the recombinant human-derived PPAR-gamma protein, expressed by E. coli , with labeled tag.

HY-P705437

	Ppar gamma Protein, Mouse (His) PPARg; Nr1c3; Peroxisome proliferator-activated receptor gamma; PPAR-gamma; Nuclear receptor subfamily 1 group C member 3	Mouse	E. coli

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-13956S

Pioglitazone-d4
Pioglitazone-d₄ is a deuterium labeled Pioglitazone. Pioglitazone (U 72107) is a potent and selective PPARγ agonist with high affinity binding to the PPARγ ligand-binding domain with EC₅₀ of 0.93 and 0.99 μM for human and mouse PPARγ, respectively .

HY-B0205S

Candesartan-d4
Candesartan-d₄ (CV-11974-d₄) is the deuterium labeled Candesartan (HY-B0205). Candesartan (CV 11974) is an orally active angiotensin II AT1-Receptor blocker and PPAR-γ agonist. Candesartan has potent and long-lasting antihypertensive effects. Candesartan can be used for the research of hypertension, chronic heart failure (CHF) and Traumatic brain injury (TBI).

HY-50935S

Troglitazone-d4
Troglitazone-d₄ is deuterium labeled Troglitazone. Troglitazone is a PPARγ agonist, with EC50s of 550 nM and 780 nM for human and murine PPARγ receptor, respectively.

HY-13956S1

Pioglitazone-d4 (alkyl)
Pioglitazone-d₄ (alkyl) (U 72107-d₄ (alkyl)) is the deuterium labeled Pioglitazone. Pioglitazone (U 72107) is a potent and selective PPARγ agonist with high affinity binding to the PPARγ ligand-binding domain with EC₅₀ of 0.93 and 0.99 μM for human and mouse PPARγ, respectively .

HY-101064S1

Fmoc-leucine-13C6,15N
Fmoc-leucine- ¹³C₆, ¹⁵N is a ¹⁵N-labeled and ¹³C-labled Fmoc-leucine. Fmoc-leucine is a selective PPARγ modulator. Fmoc-leucine activates PPARγ with a lower potency but a similar maximal efficacy than rosiglitazone. Fmoc-leucine improves insulin sensitivity

HY-B0637S

Bezafibrate-d6
Bezafibrate-d₆ is the deuterium labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.

HY-B0287S

Clofibrate-d4
Clofibrate-d₄ is the deuterium labeled Clofibrate. Clofibrate is an agonist of PPAR, with EC50s of 50 μM, ∼500 μM for murine PPARα and PPARγ, and 55 μM, ∼500 μM for human PPARα and PPARγ, respectively.

HY-17386S

Rosiglitazone-d3
Rosiglitazone-d₃ is the deuterium labeled Rosiglitazone. Rosiglitazone (BRL 49653) is a selective, orally active PPARγ agonist with EC₅₀s of 30 nM, 100 nM and 60 nM for PPARγ1, PPARγ2, and PPARγ, respectively. Rosiglitazone binds to PPARγ with a Kd of approximately 40 nM. Rosiglitazone is also an activator of TRPC5 (EC₅₀=~30 μM) and an inhibitor of TRPM3 .

HY-W738533

Pioglitazone-d4 hydrochloride
Pioglitazone-d₄ hydrochloride (U 72107A-d₄; AD 4833-d₄) is the deuterium labeled Pioglitazone hydrochloride (HY-14601). Pioglitazone hydrochloride is a potent and selective PPARγ agonist with EC₅₀s of 0.93 and 0.99 μM for human and mouse PPARγ, respectively.

HY-B0637S1

Bezafibrate-d4
Bezafibrate-d₄ is deuterium labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.

HY-14728S

Deutaleglitazar
Deutaleglitazar (Aleglitazar-d₂) is a agonist of dual peroxisome proliferatory activating receptor (PPARα and *PPARγ*) .

HY-101064S2

Fmoc-leucine-d3
Fmoc-leucine-d₃ is the deuterium labeled Fmoc-leucine. Fmoc-leucine is a selective PPARγ modulator. Fmoc-leucine activates PPARγ with a lower potency but a similar maximal efficacy than rosiglitazone. Fmoc-leucine improves insulin sensitivity in normal, diet-induced glucose-intolerant, and in diabetic db/db mice. Fmoc-leucine has a lower adipogenic activity .

HY-101064S3

Fmoc-leucine-d10
Fmoc-leucine-d₁₀ is the deuterium labeled Fmoc-leucine. Fmoc-leucine is a selective PPARγ modulator. Fmoc-leucine activates PPARγ with a lower potency but a similar maximal efficacy than rosiglitazone. Fmoc-leucine improves insulin sensitivity in normal, diet-induced glucose-intolerant, and in diabetic db/db mice. Fmoc-leucine has a lower adipogenic activity .

HY-B0637S2

Bezafibrate-13C6
Bezafibrate- ¹³C₆ (BM15075- ¹³C₆) is ¹³C labeled Bezafibrate. Bezafibrate is an agonist of *PPAR, with EC₅₀s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ* and PPARδ, and 90 μM, 55 μM, 110 μM for *murine PPARα, PPARγ* and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.

HY-13202S

T0070907-d4
T0070907-d4 is the deuterium labeled T0070907 (HY-13202). T0070907 is a potent *PPARγ* antagonist .

HY-107333S

Cinoxate-d3
Cinoxate-d₃ is deuterium labeled Cinoxate. Cinoxate is a hypertrophic peroxisome proliferator activating receptor γ (PPARγ) agonist with K_i value of 18.0 μM. Cinoxate can be used to study obesity .

HY-Y0078S1

Cinnamyl Alcohol-d9
Cinnamyl Alcohol-d₉ is deuterated labeled Cinnamyl Alcohole (HY-Y0045). Cinnamyl Alcohol is an active component from chestnut flower, inhibits increased *PPARγ* expression, exhibits anti-obesity, antioxidant and anti-inflammatory activities .

HY-Y0078S

Cinnamyl Alcohol-d5
Cinnamyl Alcohol-d₅ is deuterated labeled Cinnamyl Alcohole (HY-Y0045). Cinnamyl Alcohol is an active component from chestnut flower, inhibits increased *PPARγ* expression, exhibits anti-obesity, antioxidant and anti-inflammatory activities .

HY-15027S

5-Aminosalicylic Acid-d3 hydrochloride
5-Aminosalicylic Acid-d₃ (hydrochloride) is the deuterium labeled 5-Aminosalicylic Acid. 5-Aminosalicylic acid (Mesalamine) hydrochloride acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB.

HY-16578S

GW9662-d5
GW9662-d₅ is the deuterium labeled GW9662. GW9662 is a potent and selective PPARγ antagonist with an IC₅₀ of 3.3 nM, showing 10 and 1000-fold selectivity over PPARα and PPARδ, respectively .

HY-19937S1

Saroglitazar-d4
Saroglitazar-d₄ is the deuterium-labeled Saroglitazar (HY-19937). Saroglitazar-d₄ is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity with EC₅₀ values of 0.65 pM and 3 nM in HepG2 cells, respectively.

HY-15027S2

5-Aminosalicylic acid-13C6
5-Aminosalicylic acid- ¹³C₆ is the ¹³C labeled 5-Aminosalicylic Acid . 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB .

HY-15027S1

5-Aminosalicylic acid-d3
5-Aminosalicylic acid-d₃ is the deuterium labeled 5-Aminosalicylic Acid. 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB .

HY-17386S1

Rosiglitazone-d4
Rosiglitazone-d₄ is deuterated labeled Rosiglitazone (HY-17386). Rosiglitazone (BRL 49653) is an orally active selective *PPARγ* agonist (EC₅₀: 60 nM, K_d: 40 nM). Rosiglitazone is an TRPC5 activator (EC₅₀: 30 μM) and TRPM3 inhibitor. Rosiglitazone can be used in the research of obesity and diabetes, senescence, ovarian cancer .

HY-B0760S1

Fenofibric acid-13C8
Fenofibric acid- ¹³C₈ (FNF acid- ¹³C₈) is ¹³C labeled Fenofibric acid. Fenofibric acid, an active metabolite of fenofibrate, is a *PPAR* activitor, with EC₅₀s of 22.4 μM, 1.47 μM, and 1.06 μM for PPARα, PPARγ and PPARδ, respectively; Fenofibric acid also inhibits COX-2 enzyme activity, with an IC₅₀ of 48 nM.

HY-B0760S2

Fenofibric acid-d4
Fenofibric acid-d₄ (FNF acid-d₄) is deuterium labeled Fenofibric acid. Fenofibric acid, an active metabolite of fenofibrate, is a *PPAR* activitor, with EC₅₀s of 22.4 μM, 1.47 μM, and 1.06 μM for PPARα, PPARγ and PPARδ, respectively; Fenofibric acid also inhibits COX-2 enzyme activity, with an IC₅₀ of 48 nM.

HY-N0479S

Licarin B-d4
Licarin B-d₄ is the deuterium labeled Licarin B (HY-N0479). Licarin B, a nitric oxide production inhibitor extracted from the component of the seeds of Myristica fragrans, improves insulin sensitivity via PPARγ and activation of GLUT4 in the IRS-1/PI3K/AKT pathway .

HY-B0760S

Fenofibric acid-d6
Fenofibric acid-d₆ (FNF acid-d6) is the deuterium labeled Fenofibric acid. Fenofibric acid, an active metabolite of fenofibrate, is a PPAR activitor, with EC50s of 22.4 µM, 1.47 µM, and 1.06 µM for PPARα, PPARγ and PPARδ, respectively; Fenofibric acid also inhibits COX-2 enzyme activity, with an IC50 of 48 nM.

HY-117727S

Leriglitazone-d4

Leriglitazone-d₄ (MIN-102-d₄; Hydroxypioglitazone-d₄) is deuterium labeled Leriglitazone. Leriglitazone is an orally active and a BBB-penetrable PPARγ agonist with an EC₅₀ of 9 μM. Leriglitazone, as a regulator of mitochondrial function, has neuroprotective, anti-inflammatory and antioxidant effects. Leriglitazone can be used in the study of neuroinflammatory and neurodegenerative diseases .

HY-15027S3

5-Aminosalicylic acid-d3 disodium
5-Aminosalicylic acid-d₃ disodium is deuterated labeled 5-Aminosalicylic Acid (HY-15027). 5-Aminosalicylic acid (Mesalamine) acts as a specific *PPARγ* agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB.5-Aminosalicylic acid can inhibit the activity of osteopontin (OPN).

HY-101491S

SR-18292-d9
SR-18292-d₉ is the deuterium labeled SR-18292 (HY-101491). SR-18292 is a PPAR gamma coactivator-1α (PGC-1α) inhibitor, which increases PGC-1α acetylation, suppresses gluconeogenic gene expression and reduces glucose production in hepatocytes .

HY-15027S4

5-Aminosalicylic acid-d7
5-Aminosalicylic acid-d₇ (5-ASA-d₇; Mesalamie-d₇; Mesalazie-d₇) is deuterium labeled 5-Aminosalicylic Acid. 5-Aminosalicylic acid (Mesalamine) acts as a specific *PPARγ* agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB. 5-Aminosalicylic acid can inhibit the activity of osteopontin (OPN) .

HY-W654296

Octocrylene-13C3

Octocrylene- ¹³C₃ is the ¹³C-labeled Octocrylene (HY-A0087). Octocrylene is an organic ultraviolet (UV) filter that absorbs mainly UVB radiation and shorter UVA wavelengths. Octocrylene acts as a partial agonist of PPARγ, which alters the gene transcription profile of lipid metabolism enzymes. In addition, Octocrylene is cytotoxic and genotoxic to human skin fibroblasts and mediates the biosynthesis of estrogens such as estriol in zebrafish larvae, while affecting antioxidant pathways including glutathione transferase and peroxisomes .

HY-143704S

5-Aminosalicylic acid-13C6 hydrochloride
5-Aminosalicylic acid-13C6 hydrochloride?(Mesalamine-13C6 hydrochloride; 5-ASA-13C6 hydrochloride; Mesalazine-13C6 hydrochloride) is the 13C labeled 5-Aminosalicylic Acidhydrochloride. 5-Aminosalicylic acid-13C6 hydrochloride?acts as a PPARγ agonist, and also inhibits p21-activated kinase 1 (PAK1) and NF-κB .

HY-108568S

15-Deoxy-Δ-12,14-prostaglandin J2-d4

15-Deoxy-Δ-12,14-prostaglandin J2-d₄ is the deuterium labeled 15-Deoxy-Δ-12,14-prostaglandin J2. 15-Deoxy-Δ-12,14-prostaglandin J2 (15d-PGJ2) is a cyclopentenone prostaglandin and a metabolite of PGD2. 15-Deoxy-Δ-12,14-prostaglandin J2 is a selective PPARγ (EC₅₀ of 2 μM) and a covalent PPARδ agonist. 15-Deoxy-Δ-12,14-prostaglandin J2 promotes efficient differentiation of C3H10T1/2 fibroblasts to adipocytes with an EC₅₀ of 7 μM .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80436

	PPAR gamma Antibody (YA122) 1 Publications Verification	WB	Human, Rat
	PPAR gamma Antibody (YA122) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PPAR gamma.

HY-P85457

	PPAR gamma Antibody (YA5149) PPARG; NR1C3; Peroxisome proliferator-activated receptor gamma; PPAR-gamma; Nuclear receptor subfamily 1 group C member 3	WB, ICC/IF	Human, Mouse, Rat, Bovine, Dog, Goat, Pig, Rabbit, Sheep
	PPAR gamma Antibody (YA5149) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to PPAR gamma.

HY-P80783

	PGC1 alpha Antibody 1 Publications Verification PPARGC1A; LEM6; PGC1; PGC1A; PPARGC1; Peroxisome proliferator-activated receptor gamma coactivator 1-alpha; PGC-1-alpha; PPAR-gamma coactivator 1-alpha; PPARGC-1-alpha; Ligand effect modulator 6	WB	Human, Mouse, Rat
	PGC1 alpha Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to PGC1 alpha.

HY-P85326

	PGC1 alpha Antibody (YA5018) PPARGC1A; LEM6; PGC1; PGC1A; PPARGC1; Peroxisome proliferator-activated receptor gamma coactivator 1-alpha; PGC-1-alpha; PPAR-gamma coactivator 1-alpha; PPARGC-1-alpha; Ligand effect modulator 6	WB	Mouse, Rat
	PGC1 alpha Antibody (YA5018) is a Rabbit-derived and non-conjugated monoclonal antibody, targeting to PGC1 alpha.

HY-P80783A

	PGC1 alpha Antibody (YA7180) PPARGC1A; LEM6; PGC1; PGC1A; PPARGC1; Peroxisome proliferator-activated receptor gamma coactivator 1-alpha; PGC-1-alpha; PPAR-gamma coactivator 1-alpha; PPARGC-1-alpha; Ligand effect modulator 6	WB	Human, Mouse, Rat
	PGC1 alpha Antibody is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PGC1 alpha.

HY-P83728

	PGC1 alpha+beta Antibody (YA3458) LEM6 antibody; Ligand effect modulator 6 antibody; PERC antibody; Peroxisome proliferative activated receptor, gamma, coactivator 1 antibody; PGC 1 alpha antibody; PGC-1-beta antibody; PGC-1-related estrogen receptor alpha coactivator antibody; PGC1 antibody; PGC1A antibody; PGC1v antibody; PPAR gamma coactivator 1 alpha antibody; PPAR gamma coactivator-1 beta antibody; PPARGC 1 alpha antibody; PPARGC-1-beta antibody; PPARGC1 antibody; PPARGC1A antibody; PPARgc1b antibody; PRGC1_HUMAN antibody; PRGC2_HUMAN antibody;	WB	Human, Mouse, Rat
	PGC1 alpha+beta Antibody (YA3458) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PGC1 alpha+beta.

HY-P80872

	PPAR gamma Antibody CIMT1; GLM1; NR1C3; Nuclear receptor subfamily 1 group C member 3; Peroxisome proliferator activated nuclear receptor gamma variant 1; Peroxisome proliferator activated receptor gamma 1; Peroxisome Proliferator Activated Receptor gamma; Peroxisome prolife	ICC/IF, WB, IHC-F, IHC-P, ELISA	Human, Mouse, Rat
	PPAR gamma Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to PPAR gamma.

HY-P87712

	PPAR-γ Antibody (YA7397)	WB, IHC, ICC/IF, IP, ELISA	Human, Mouse

HY-P85702

	PPAR gamma Antibody (YA5394) Peroxisome proliferator-activated receptor gamma; PPAR-gamma; Nuclear receptor subfamily 1 group C member 3;	IHC-P, WB	Human, Mouse, Rat
	PPAR gamma Antibody (YA5394) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to PPAR gamma.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-173115

15-LOX-IN-2		Alkynes
15-LOX-IN-2 (Compound 2a) is an orally active COX-2/15-LOX inhibitor and a partial agonist of *PPARγ. 15-LOX-IN-2 has anti-inflammatory activity and inhibits the levels of 20-HETE, IL-1β* and TNF-α in RAW 264.7 cells treated with LPS (HY-D1056). In addition, 15-LOX-IN-2 has significant glucose uptake capacity in the absence of insulin. 15-LOX-IN-2 can be used for the research of metabolic diseases .

Cat. No.	Product Name		Classification

HY-128671

6-Thioinosine 6TI; 6-Mercaptopurine riboside		Nucleoside Analogs Inosine
6-Thioinosine (6TI) is a purine antimetabolite and an anti-adipogenic agent. 6-Thioinosine reduces the mRNA levels of *PPARγ* and C/EBPα and downregulates the mRNA levels of *PPARγ* target genes (LPL, CD36, aP2, and LXRα). 6-Thioinosine exerts its anti-adipogenic effects by downregulating *PPARγ* through JNK-dependent iNOS upregulation. 6-Thioinosine can be used to study adipocyte dysfunction .

HY-132591A

Inclisiran sodium 5+ Cited Publications ALN-PCSsc sodium		siRNAs siRNA drugs
Inclisiran sodium is a double-stranded small interfering RNA (siRNA) molecule. Inclisiran sodium inhibits the transcription of PCSK9. Inclisiran sodium inhibits Pyroptosis, activates *PPARγ, and reduces NLRP3, cleaved caspase-1, IL-1β, and IL-18*. Inclisiran sodium has anti-inflammatory, lipid-regulating and anti-atherosclerotic activities. Inclisiran sodium can be used in researches of hyperlipidemia and cardiovascular disease (CVD) .

HY-132591

Inclisiran 5+ Cited Publications ALN-PCSsc		siRNAs siRNA drugs
Inclisiran is a double-stranded small interfering RNA (siRNA) molecule. Inclisiran inhibits the transcription of PCSK9. Inclisiran inhibits Pyroptosis, activates *PPARγ, and reduces NLRP3, cleaved caspase-1, IL-1β, and IL-18*. Inclisiran has anti-inflammatory, lipid-regulating and anti-atherosclerotic activities. Inclisiran can be used in researches of hyperlipidemia and cardiovascular disease (CVD) .

HY-W440983

SDPC PC(18:0/22:6); DHA-PC; 1-Stearoyl-2-docosahexaenoyl-sn-glyerco-3-phosphocholine		Phospholipids
SDPC (DHA-PC) is a new generation of omega-3 lipids, which contains an ester bond linking DHA at the sn-2 position of phospholipid. 1-Stearoyl-2-docosahexaenoyl-sn-glyerco-3-phosphocholine exerts anti-angiogenesis effect through activating *PPARγ*. 1-Stearoyl-2-docosahexaenoyl-sn-glyerco-3-phosphocholine significantly declines the proliferation, migration, tube formation of human umbilical vein endothelial cells. 1-Stearoyl-2-docosahexaenoyl-sn-glyerco-3-phosphocholine has the potential for anti-tumor angiogenesis research .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

PPAR-γ

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Natural
Products